References

nid

Нефрология и диализ

Nephrology and Dialysis

1680-44222618-9801

Российское диализное общество

nid-1586

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

ANCA-ассоциированные и криоглобулинемические васкулиты: диагностика и лечение (Обзор литературы)

ANCA-associated and cryoglobulinemic vasculitis: diagnostics and treatment review

Захарова

Е. В.

Zakharova

E. V.

zakharoval@mtu-net.ru

Московская городская клиническая больница им. С.П. Боткина, г. МоскваRussian Federation

2005

23062025

71625

2025

Захарова Е.В.

Zakharova E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nephro.ru/jour/article/view/1586

Системные васкулиты - гетерогенная группа заболеваний, основным морфологическим признаком которых является воспаление сосудистой стенки, а клинические проявления определяются типом, размерами и локализацией пораженных сосудов и тяжестью иммуновоспалительных изменений [8]. До настоящего времени многие авторы указывают на неадекватность существующих схем классификации и диагностики васкулитов [25]. Наиболее часто применяется классификация Американской Коллегии Ревматологии (АКР), которая выделяет семь синдромов, позволяющих проводить дифференциальный диагноз васкулитов [

криоглобулинемияваскулитыкортикостероидыцитостатики

References1

Ватанская И.Ю., Дубовая Л.И., Сухоплюева Н.И. и др. Случай синдрома Чарга-Стросс (анализ клинического наблюдения). Украинский журнал экстремальной медицины 2003; 4 (3): 91-93.

Гордовская Н.Б., Козловская Л.В., Азарова В.В. и др. Особенности клинического течения нефрита у больных с криоглобулинемией. Тер. арх. 1997; 6: 3-34.

Игнатова Т.М., Милованова С.Ю., Мозолевский Ю.В. и др. Успешное лечение интерфероном á и рибаверином криоглобулинемического васкулита, обусловленного HCV-инфекцией. РЖГГК 2004; 14 (2): 64-67.

Козловская Л.В., Мухин Н.А., Гордовская Н.Б. и др. Факторы риска прогрессирования криоглобулинемического гломерулонефрита, связанного с вирусом гепатита С. Клин. мед. 2001; 4: 32-35.

Мельянкин А.В. Легочная форма гранулематоза Вегенера: КТ и рентгенологические признаки (клиническое наблюдение и обзор литературы). Медицинская визуализация 2002; 4: 56-59.

Милованов Ю.С., Тареева И.Е., Кутырина И.М. и др. Острая почечная недостаточность у больных с хроническим гломерулонефритом. Тер. арх. 1992; 64 (6): 32-35.

Мухин Н.А., Козловская Л.В., Малышко Е.Ю. Криоглобулинемический нефрит, ассоциированный с хронической инфекцией вируса гепатита С. Тер. арх. 2000; 6: 1-5.

Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Ярославль: Верхняя Волга, 1999: 9, 35-37.

Семенкова Е.Н. Системные васкулиты. М.: 1988.

Семенкова Е.Н. Современные проблемы системных васкулитов. Клин. мед. 1989; 4: 18-24.

Семенкова Е.Н., Бекетова Т.В., Коган Е.А. и др. Современные представления о микроскопическом полиартериите. Тер. арх. 1995; 5: 39-41.

Aasarod K., Bostad L., Hammerstorm J. et al. Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 2001; 16: 953-960.

Adu D., Howie A.J., Scott D.G. et al. Poliarteriitis and the kidney. Q J Med 1987; 62: 221-237.

Adu D., Pall A., Luqqmani R.A. et al. Controlled trial of pulse versus continuous prednisone and cyclophosphamide in treatment of systemic vasculitis. QJM 1997; 90: 401-409.

Agnello V. The ethiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Seminars in Immunopathol. 1997; 19: 111-129.

Allen N.B., Caldwell D.S., Rice J.R. et al. Cyclosporin A therapy for Wegener’s granulomatosis. Adv Exp Med Biol 1993; 336: 473-476.

Allen A., Pusey C., Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998; 9: 1258-1263.

Alric L., Plaisier E., Thebault S. et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J kidney Dis 2004; 43 (4): 617-623.

Amarapurkar D.N., Amarapurkar A.D. Extrahepatic manifestations of viral hepatitis. Ann Hepatol 2002; 1 (4): 192-195.

Anderson G., Coles E.T., Crane M. et al. Wegener’s Granuloma. A series of 265 British cases seen between 1975 and 1985. Q J Med 1992; 83: 427-438.

Andrassy K., Rasmussen N. Treatment of granulomatous disorders of the nose and paranasal sinuses. Rhinology 1989; 27 (4): 221-230.

Andrassy K., Waldherr R., Erb A. et al. De novo glomerulonephritis in patients during remission from Wegener’s granulomatosis. Clin Nephrol 1992; 38: 295-298.

Antonelli G., Gianelli G., Currenti M. et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing IFN-therapy. Clin Exp Immunol 1996; 104: 384-387.

Bacon P.A. Aetiopathogenesis of vasculitis. J Rheumatol 1992; 4: 187-194.

Ball G.V., Bridges Jr.S.L. Ed Vasculitis. New York: Oxford University Press 2002; 1-4, 34-45.

Ballare M., Bobbio F., Poggi S. et al. A pilot study of the effectivness of cyclosporine in type II mixed cryoglobulinemia. Clin Exp Rheum 1995; 13 (Suppl. 13): 201-203.

Bandi L. Renal manifeststions of hepatitis C virus infection. Extrahepatic complications often are silent - and thus overlooked. Postgrad Med 2003; 113 (2): 73-76, 86.

Birck R., Warnatz K., Lorenz H.M. et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14 (2): 440-447.

Bloch F.J. Cryoglobulinemia and hepatitis virus. N Engl J Med 1992; 327: 1521-1522.

Bombardieri S., Ferri C., Di Munno O. et al. Liver involvement in essential cryoglobulinemia. La Ricera in Clinica e Laboratorio 1979; 9: 361-372.

Bombardieri S., Paoletti P., Ferri C. et al. Lung involvement in essential mixed cryoglobulinemia. Am J Med 1979; 66: 748-756.

Bonomo L., Casato M., Afeltra A. et al. Treatment of idiopatic mixed cryoglobulinemia with alpha-interferon. Am J Med 1987; 83: 726-731.

Booth A.D., Almond M.K., Burns A. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41 (4): 776-784.

Booth A.D., Jefferson H.J., Ayliffe W. et al. Safety and efficacy of TNFá blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61: 559.

Bridoux F., Provot F., Abou Ayach R. et al. Renal damage during type II cryoglobulinemia. Presse Med 2003; 32 (12): 563-569.

Briedigkeit L., Kettritz R., Gobel U. et al. Prognostic factors in Wegener’s granulomatosis. Postgrad Med J 1993; 69: 856-861.

Brijker F., Magee C.C., Cohen Tervaert J.W. et al. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies. Clin Nephrol 1999; 52 (6): 344-351.

Brouet J.-C., Clauvel J.-P., Danon F. et al. Biologic and clinical significance of crioglobulins: a report of 86 cases. Am J Med 1974; 57: 775-788.

Bruchfeld A., Lindahl K., Stahle L. et al. Inteferon and ribaverin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18 (8): 1573-1580.

Cagnoli L. Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropathies. G Ital Nefrol 2003; 20 (Suppl. 24): 3-47.

Carrie S., Huges K.B., Watson M.G. Negative ANCA Wegener’s granulomatosis. J Laryngol Otol 1994; 108 (5): 420-422.

Chernok E., Szimkowiak C., Mistry N. et al. TGF-â expression and interactions with proteinase 3 in ANCA-positive vasculitis. Clin Ezp Immunol 1996; 105: 104-111.

Choi H.K., Merkel P.A., Niles J.L. ANCA-positive vasculitis associated with allopurinol therapy. Clin Exp Rheumatol 1998; 16: 743-744.

Choi H.K., Lamprecht P., Niles J.L. et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthr Rheum 2000; 43: 226-231.

Christensson M., Petersson E., Sundqvist K.G. et al. T cell activation in patients with ANCA-associated vasculitis: inefficient immune suppression by therapy. Clin Nephrol 2000; 54 (6): 435-442.

Chumbley L.C., Harrison E.G. Jr., deRemee R.A. Allergic granulomatosis and angiitis (Churg-Strauss syndrome), report and analysis of 30 cases. Mayo Clinic Proc 1977; 52: 477-484.

Churg J., Churg A. Zafirlukast and Churg-Strauss syndrome. JAMA 1998; 279: 1949-1950.

Churg J., Strauss L. Allergic granulomatosis, allergic angiitis, and periarteriitis nodosa. Am J Pathol 1951; 27: 277-301.

Clutterbuck E.J., Evans D.J., Pusey C.D. Renal involvement in Churg-Strauss syndrome. Nephr Dial Transplant 1990; 5: 161-167.

Cocoub P., Ghilliani P., Revelen R. et al. Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol 1999; 31 (4): 598-603.

Cohen B.A., Clark W.F. Pauci-immune renal vasculitis: natural history, prognostic factors, and impact of therapy. Am J Kidney Dis 2000; 36 (5): 914-924.

Cordier J.-F., Valeyr D., Guillevin L. et al. Pulmonary Wegener’s granulomatosis. A clinical imaging study of 77 cases. Chest 1990; 97: 906-912.

Cottin V., Cordier J.F. Churg-Strauss syndrome. Rev Pneumol Clin 2003; 59 (1): 17-24.

Covic A., Marian D., Florea L. et al. The relationships of rapidly progressive glomerulonephritis (RPGN), crescentic glomerulonephritis and vasculitis: the clinical, histopathological and therapeutic considerations. Rev Med Chir Soc Med Nat Iasi 1996; 199 (3-4): 63-72.

Czaja A.J. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis 1997; 15 (3): 125-144.

D’Amico G., Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995; 25 (3): 361-369.

Daum T.E., Specks U., Colby T.V. et al. Transbronchial involvement in Wegener’s granulomatosis. Am J Respiratory and Critical Care Med 1995; 151: 742-750.

Davis M.D., Daoud M.S., McEvoy M.T. et al. Cutaneous manifestations in Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 1997; 37: 199-203.

Davson J., Ball J., Platt R. The kidney in periarteriitis nodosa. QJM 1948; 17: 175-202.

de Groot K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: metha-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-2027.

de Groot K., Gross W.L., Herlyn K. et al. Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 2001; 55: 31-38.

de Groot K., Gross W.L., Schnabel A. Pulmonary renal syndrome. Internist (Berlin) 2003; 44 (9): 1140-1150.

de Groot K., Reinhold-Keller E., Tatsis E. et al. Therapy for the maitnance of remission in sixty-five patients with generalized Wegener’s granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthr Rheum 1996; 39: 2052-2061.

Delen S., Boonen A., Landewe R. et al. An unusual case of ANCA positive disease. Ann Rheum Dis 2003; 62: 780-881.

DeRemee R.A. Churg-Strauss syndrome. In: Vasculitis. Ed. Ball G.V. and Bridges Jr S.L. New York. Oxford University Press 2002: 376-384.

Dienstag J.L., Wands J.R., Isselbacher K.J. Hepatitis B and essential mixed cryoglobulinemia. N Engl J Med 1977; 297: 946-947.

Dispenzieri A., Gorevic P.D. Cryoglobulinemia. Hematol Oncol Clin North Am 1999; 13 (6): 1315-1349.

Dupin N., Chosidov O., Lunel F. et al. Essential mixed cryoglobulinemia. A comparative study of dermatologic manifestations in patients infected or noninfected with hepatitis C virus. Arch Dermatol 1991; 131: 1124-1127.

Eustace J.A., Nadasdy T., Choi M. Disease of a month. Churg-Strauss syndrome. J Am Soc Nephrol 1999; 10: 2048-2055.

Falk R.J., Hogan S.L., Carey T.S. et al. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Int Med 1990; 113: 656-663.

Falk R.J., Nachman P.H., Hogan S.L. et al. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol 2000; 20 (3): 233-243.

Fang J.T., Huang C.C. Blue toe syndrome associated with rapidly progressive glomerulonephritis: ultimately revealed essential mixed cryoglobulinemia. Ren Fail 1997; 19 (1): 177-181.

Fauci A.S., Haynes B.F., Katz P. et al. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Int Med 1983; 98: 76-85.

Ferraz-Amaro I., Herrero M.J., Jurado A. et al. Dual positivity for cytoplasmic and perinuclear antibodies in patient with Henoch-Schonlein purpura. Clin Exp Rheum 2004; 22 (2): 233-234.

Ferri C., La Civita L., Cirafissi C. et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheum 1992; 19: 889-895.

Ferri C., Pietrogrande M., Cecchetti R. et al. Low-antigen diet in the treatment of mixed cryoglobulinemia patients. An J Med 1989; 87: 519-528.

Ferri C., Zignego A.L., Pileri S.A. Cryoglobulins. J Clin Pathol 2002; 55: 4-13.

Finter N.B. The naming of cats - and alpha-interferons. Lancet 1996; 348: 348-349.

Fornasieri A., D’Amico G. Type II mixed cryoglobulinemia, hepatitis C virus infection and glomerulonephritis. Nephrol Dial Transplant 1996; 11(Suppl. 4): 25-30.

Frankel A.H., Singer D.R., Winearls C.S. et al. Type II essential mixed cryoglobulinemia: presentation, treatment and outcome in 13 patients. Q J Med 1992; 82 (298): 101-124.

Franssen C., Gans R., Kallenberg C. et al. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Int Med 1998; 244: 209-216.

Frasca G.M., Zoumparidis N.G., Borgnino L.C. et al. Combined therapy in Wegener’s granulomatosis with crescentic glomerulonephritis - clinical course and long-term outcome. Int J Artif Organs 1993; 16 (1): 11-19.

Gabrielli A., Zhang Z.-X., Cherubini G. et al. Differential humoral immune response against hepatitis virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinemia. Clin Exp Immunol 1996; 105: 59-64.

Galli M., Invernizzi F., Monteverde A. et al. Cryoglobulinemic Vasculitis. In: Vasculitis. New York. Oxford University Press 2002: 500-503.

Gamble C.N., Kimichi A., Depner T.A. et al. Immune complex glomerulonephritis and dermal vasculitis following intestinal bypass for morbid obesity. Am J Clin Pathol 1982; 77 (3): 347-352.

Garrett P.J., Dewhurst A.G., Morgan L.S. et al. Renal disease associated with circulating antineutrophil cytoplasm activity. Q J Med 1992; 85 (306): 731-749.

Garini G., Allegri L., Carnevali L. et al. Interferon-alpha in combination with ribaverin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoprolipherative glomerulonephritis. Am J Kidney Dis 2001; 38 (6): E35.

Gaskin G., Clutterbuck E.J., Pusey C.D. Renal disease in the Churg-Strauss syndrome: Diagnosis, management and outcome. Contrib Nephrol 1991; 94: 58-65.

Gayraud M., Guillevin L., Cohen P. et al. Treatment of good-prognosis poliarteriitis nodosa and Churg-Strauss syndrome: comparison of steroids and oral o pulse cyclophosphamide in 25 patients. Br J Rheum 1997; 36: 1290-1297.

Geffriaud-Ricouard C., Noel L.H., Chauveau D. et al. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39 (3): 125-136.

Genereau T., Lortholary O., Leclerq P. et al. Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high dose regimen in four patients. Br J Rheum 1994; 33: 959-962.

Germain M.J., Anderson R.W., Keane W.F. Renal disease in cryoglobulinemia type II: response to therapy. A case report and review of literature. Am J Nephrol 1982; 2 (4): 221-226.

George J., Levy Y., Kallenberg C.G.M. et al. Infections and Wegener’s granulomatosis - a cause and effect relationship? Q J Med 1997; 90: 367-373.

Ghijsels E., Lerut E., Vanrenterghem Y. et al. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43 (5): 34-38.

Ghinoi A., Masica M.Y., Puccini R. et al. Autoimmune and limphoprolipherative HCV-correlated manifestations: example of mixed cryoglobulinemia (review). G Ital Nefrol 2004; 21 (3): 225-237.

Gilligan H.M., Bredy B., Bardy H.R. et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents of a surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996; 184: 2231-2241.

Godman G.C., Churg J. Wegener’s granulomatosis. Arch Pathol 1954; 58: 533-553.

Gordon M., Luqmani R.A., Adu D. et al. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86 (12): 779-789.

Gross W.L. Wegener’s granulomatosis. New aspects of disease course, immunodiagnostic procedures and stage-adapted treatment. Sarcoidosis 1989; 6: 15-29.

100

Gross W.L. New concepts in the treatment protocols for severe systemic vasculitis. Curr Opin Rheum 1999; 11: 41-46.

101

Gross W.L., Csernok E., Trabandt A. Pathogenesis of Wegener’s granulomatosis. Ann Med Int 1998; 149: 280-286.

102

Gross W.L., Rasmussen N. Treatment of Wegener’s granulomatosis; the view from two non-nephrologist. Nephrol Dial Transplant 1994; 9: 1219-1222.

103

Grotz W., Wanner C., Keller E. et al. Crescentic glomerulonephritis in Wegener’s granulomatosis: morphology, therapy, outcome. Clin Nephrol 1991; 35: 243-251.

104

Guillevin L., Cevallos R., Durand-Gasselin B. et al. Treatment of glomerulonephritis in microscopic poliangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, metha-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Lnt (Paris) 1997; 148 (3): 198-204.

105

Guillevin L., Cohen P., Gayaraud M. et al. Churg Strauss syndrome: Clinical study and long-term follow-up of 96 patients. Medicine 1999; 78: 26-37.

106

Guillevin L., Cordier J.F., Lhote F. et al. A prospective multicenter randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in treatment of generalized Wegener’s granulomatosis. Arthr Rheum 1997; 40: 2187-2198.

107

Guillevin L., Durand-Gasseline B., Cevallos R. et al. Microscopic poliangiitis; clinical and laboratory findings in 85 patients. Arthr Rheun 1999; 42: 421-430.

108

Guillevin L., Fain O., Lhote F. et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of poliarteriitis nodosa and Churg-Strauss syndrome. A prospective randomized trial in 78 patients. Arthr Rheum 1992; 35: 208-215.

109

Guillevin L., Lhote F., Cohen P. et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of poliarteriitis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective randomized trial in 62 patients. Arthr Rheum 1995; 38: 1638-1645.

110

Guillevin L., Lhote F., Jarrousse B. et al. Treatment of poliarteritis nodosa and Churg-Strauss syndrome. A metha-analysis of 3 prospective controlled studies including 182 patients over 12 years. Ann Med Int (Paris) 1992; 143: 405-416.

111

Guillevin L., Lhote F., Gayaraud M. et al. Prognostic factors in poliarteritis nodosa and Churg-Strauss syndrome: A prospective study in 342 patients. Medicine 1996; 75: 17-28.

112

Guillevin L., Pagnoux C. Indications of plasma exchange for systemic vasculitides. Ther Apher Dial 2003; 7 (2): 155-160.

113

Gupta R.K. Pauci-immune crescentic glomerulonephritis. Indian J Pathol Microbiol 2003; 46 (3): 357-366.

114

Han W.K., Choi H.K., Roth R.M. et al. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003; 63 (3): 1079-1085.

115

Harman L.E., Margo C.E. Wegener’s granulomatosis. Survey Ophthalmol 1998; 42: 458-480.

116

Harper S.L., Letko E., Samson C.M. et al. Wegener’s granulomatosis: The relationship Between Ocular and Systemic Disease. J Rheum 2001; 28: 1025-1032.

117

Harris A., Chang G., Vadas M. et al. ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotizing vasculitis. J Clin Pathol 1999; 52: 670-676.

118

Haubitz M., de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57 (6): 421-424.

119

Haubitz M., Koch K.M., Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener’s granulomatosis. Nephrol Dial Transplant 1998; 13: 1713-1718.

120

Haubitz M., Koch K.M., Brunkhorst R. Cyclosporin for prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998; 13 (8): 2074-2076.

121

Haubitz M., Schellong S., Gobel U. et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a prospective randomized study. Arth Rheum 1998; 41: 1835-1844.

122

Hauer H.A., Bajema I.M., Van Houwelingen H.C. et al. Determinants of outcome in ANCA-asociated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62 (5): 1732-1742.

123

Haynes B.F. Vasculitis: pathogenic mechanisms of vessel damage. In: Inflammation: basic principles and clinical correlates, 2nd edition (ed J.I. Gallin and L.M.S.R. Golgstein)/ New York: Raven Press 921-941.

124

Hewins P., Tervaert J.W., Savage C.O. et al. Is Wegener’s granulomatosis an autoimmune disease? Curr Opin Rheumatol 2000; 12: 3-10.

125

Hoffman G.S. Vasculitic syndromes [editorial]. Current Opin Rheumatol 1997; 9: 1-2.

126

Hoffman G.S., Kerr G.S., Leavitt R.Y. et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Int Med 1992; 116: 488-498.

127

Hoffman G.S., Leavitt R.Y., Fleisher T.A. et al. Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-410.

128

Hoffman G.S., Leavitt R.Y., Kerr G.S. et al. The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthr Rheum 1992; 35 (11): 1322-1329.

129

Hogan S.L., Nachman P.H., Wilkman A.S. et al. Prognostic markers in patients with antineutrophil cytoplasmic antibody-associated microscopic poliangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32.

130

Hollander D., Manning R.T. The use of alkilating agents in the treatment of Wegener’s granulomatosis. Ann Int Med 1967; 67: 393-398.

131

Hunder G.G., Arend W.P., Bloch D.A. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthr and Rheum 1990; 33: 1065-1067.

132

Invernizzi F., Monti G. Colchicine and mixed cryoglobulinemia. Arthr Rheum 1993; 36: 722-723.

133

Israel H. Sulphamethoxazole-trimethoprim therapy for Wegener’s granulomatosis. Arch Int Med 1988; 148: 2293-2295.

134

Jara L.J., Vera-Lastra O., Calleja M.C. Pulmonary-renal vasculitic disorders: differential diagnosis and management. Curr Rheumatol Rep 2003; 5 (2): 107-115.

135

Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93 (7): 433-439.

136

Jayne D.R., Lockwood C.M. Intravenous immunoglobulin as a sole therapy for systemic vasculitis. Br J Rheum 1996; 35: 1150-1153.

137

Jayne D.R., Rasmussen N. Treatment of antineutrophil cytoplasmic antibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Trials Study Group. Mayo Clin Proc 1997; 72: 737-747.

138

Jennett J.C. Renal involvement in systemic vasculitis. In: Jennet J.C., Olson J.L., Schwartz M.M., Silva F.G., ed. Heptinstall’s Pathology of the Kidney. Lippencott-Raven, Phyladelphia: 1998: 1059-1095.

139

Jennett J.C., Falk R.J. The pathology of vasculitis involving the kidney. Am J Kidney Dis 1994; 24: 130.

140

Jennett J.C., Falk R.J. Pathogenesis of the vascular glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transpl 1998; 13 (Suppl. 1): 16-20.

141

Jennett J.C., Falk R.J., Andrassy K. et al. Nomenclature of systemic vasculitides. Proposal of an International Consensus Conference. Arthr and Rheun 1994; 37: 187-192.

142

Jennett J.C, Wilkman A.S., Falk R.J. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989; 135: 921-930.

143

Jennings C.R., Jones N.S., Dugar J. et al. Wegener’s granulomatosis - a review of diagnosis and treatment in 53 subjects. Rhinology 1998; 36 (4): 188-191.

144

Kallenberg C.G. Vasculitis: clinical approach, pathophysiology and treatment. Wien Klin Wochenschr 2000; 112 (15-16): 256-259.

145

Kallenberg C.G.M., Tervaert J.W.C. What is new in systemic vasculitis? (A report from the 9-th International Vasculitis/ANCA Workshop). Ann Rheum Dis 2000; 59 (11): 924-925.

146

Kaufmann J., Schulze E., Voigt U. et al. Orbital inflammatory pseudotumor due to hypersensitivity vasculitis end mononeuritis multiplex in a patient with atypical cANCA-positive Wegener’s granulomatosis. Rheum Int 2003; 23 (3): 138-142.

147

Keogh K.A., Specks U. Churg-Strauss syndrome: clinical presentation. Antineutrophil cytoplasmic antibodies, and leucotriene receptor antagonists. Am J Med 2003; 115 (4): 284-290.

148

Khilani G.C., Banga A., Sharma S.C. et al. Wegener’s granulomatosis: an isolated lung mass responding to antituberculosis therapy and atypical course. J Assoc Physicians India 2003; 51: 731-733.

149

Klemmer P.J., Chalermskulart W., Reif M.S. et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42 (6): 1149-1153.

150

Kourakata H., Saeki T., Miyamura S. et al. Two cases of silicosis exhibiting MPO-ANCA associated disorder. Ryumachi 1999; 39 (6): 841-846.

151

Kroot E.J.A., Mak C.L.P., Boelhouwer R.U. et al. Involvement of the omentum in Wegener’s granulomatosis. Ann Rheum 2003; 62: 1238-1239.

152

Laevitt R.Y., Fauci A.S., Bloch D.A. et al. The American College of Rheumatology 1990; criteria for the classification of Wegener’s granulomatosis. Arthr Rheum 1990; 33: 1101-1107.

153

Lanham J.G., Churg J. Churg-Struass syndrome. In: Systemic vasculitis, ed. Churg A., Churg J. New York, Igaku-Shoin: 1991: 101-120.

154

Langford C.A., Sneller M.C. Wegener’s granulomatosis: Treatment. In: Ball G.V. and Bridges Jr.S.L., ed. Vasculitis. New York: Oxford University Press 2002: 368-375.

155

Langford C.A., Tallar-Williams C., Barron K. et al. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthr Rheum 1999; 42: 2666-2673.

156

Langford C.A., Tallar-Williams C., Sneller M.C. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthr Rheum 2000; 43: 1836-1840.

157

Lauque D., Cadranel J., Lazor R. et al. Microscopic poliangiitis with alveolar hemorrhage. A study of 29 cases and review of literature. Medicine (Baltimore) 2000; 79 (4): 222-233.

158

Lee T.C., Miller W.E., Curd J.C. et al. Prolonged complete remission after 2-chlorodeoxyadenosine therapy in patient with refractory essential mixed cryoglobulinemia. Mayo Clin Proc 1966; 71 (10): 92-93.

159

Lerner A.B., Watson C.J. Studies of cryoglobulins. Unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitate serum globulin). Am J Med Sci 1947; 214: 410-415.

160

Levy Y., George J., Fabrizzi F. et al. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J 1999; 92 (4): 412-414.

161

Lewis F.M. Vulvar involvement in Wegener’s granulomatosis. J Reproduct Med 2002; 24: 725-727.

162

Lhote F., Cohen P., Genereau T. et al. Microscopic poliangiitis: clinical aspects and treatment. Ann Med Intern (Paris) 1996; 147 (3): 165-177.

163

Lhote F., Guillevin L., Godeau P. Allergic angiitis with granulomatosis: the Churg and Strauss syndrome. Rev Med Interne 1994; 15 (Suppl. 2): 226s-233s.

164

Lie J.T. Retroperitoneal poliarteriitis nodosa presenting as ureteral obstruction. J Rheum 1992; 19: 1628-1631.

165

Lim K.S., Lee G.A., Pavesio C.E. et al. Wegener’s granulomatosis. Br J Ophthalmol 2003; 87: 500.

166

Lockwood C.M. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996; 104: 77-82.

167

Lockwood C.M., Thiru S., Isaacs J. et al. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 1: 1620-1622.

168

Lockwood C.M., Thiru S., Stewart S. et al. Treatment of refractory Wegener’s granulomatosis with humanized monoclonal antibodies. Q J Med 1996; 89: 903-912.

169

Lunel F., Musset L. Mixed cryoglobulinemia and hepatitis C virus infection. Minerva Med 2001; 92 (1): 35-42.

170

Luqmani R. Wegener’s granulomatosis Classical versus non-renal Wegener’s granulomatosis. Q J Med 1994; 87: 161-167.

171

McCluskey R.T., Feinberg R. Vasculitis in primary vasculitides, granulomatosis, and connective tissue diseases. Human Pathol 1983; 14: 305-315.

172

McDermott E.M., Powell R.J. Cyclosporin in the treatment of Churg-Strauss syndrome. Ann Rheum 1998; 57: 258-259.

173

McMurray R.W. Hepatitis C-associated autoimmune disorders. Rheum Dis Clin North Am 1998; 24 (2): 353-374.

174

Maguchi S., Takizawa M., Ryu T. et al. Clinical significance of antineutrophil cytoplasmic antibody (ANCA) for the diagnosis of Wegener’s granulomatosis in the early stage. Nippon Jibiinkoka Gakkai Kaiho 1993; 96 (8): 1288-1296.

175

Mareen P., Van De Walle S., Bernaert P. et al. Antineutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis. Acta Clin Belg 2003; 58 (3): 193-200.

176

Mayet W., Schwarting A., Barreiros A.P. et al. Anti-PR-3-antibodies induce endothelial IL-8 release. Eur J Clin Invest 1999; 29: 259-267.

177

Mazzaro C., Franzin F., Tukissi P. et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to á-interferon therapy. Cancer 1996; 77: 2604-2613.

178

Mekhail T.M., Hoffman G.S. Long-term outcome of Wegener’s granulomatose in patients with renal disease requiring dialysis. J Rheum 2000; 27: 1237-1240.

179

Meltzer M., Franklin E.C. Cryoglobulinemia: a study of 29 patients. Am J Med 1966; 40: 828-836.

180

Meyers C.M., Seef L.B., Stehman-Breen C.O. et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42 (4): 631-657.

181

Milesi-Lecat A.M., Aumaitre O., Deusebis T. et al. Semi-invasive diffuse pulmonary aspergillosis with antineutrophil cytoplasmic antibodies. 2 cases. Ann Med Intern 1994; 145 (2): 140-146.

182

Monteverde A., Ballare M., Pileri S. Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Seminars in Immunopathol 1997; 19: 99-110.

183

Monteverde A., Invernizzi F., Pileri S. et al. Le crioglobulinemie miste. In: Atti dei Congressi della Societta Italiana di Medica Interna, 97° Congresso. Venezia: 15-19 Ottobre, 1997; 1-80.

184

Monti G., Saccardo F., Pioltelli P. et al. The narural history of cryoglobulinemia: symptoms at onset and during follow-up. A report by the Italian Group for the Study of Cryoglobulinemias. Clin Exp Rheum 1995; 13 (Suppl. 13): 129-133.

185

Monti G., Saccardo F., Rinaldi G. et al. Colchicine in treatment of mixed cryoglobulinemia. Clin Exp Rhem 1995; 13 (Suppl. 13): 197-199.

186

Moosig F., Chernok E., Wang G. et al. Costimulatory molecules in Wegener’s granulomatosis (WG): lack of expression of CD28 and preferential upregulation of it’s ligands B7-1 (CD80) and B7-2 (CD86) on T-cells. Clin Exp Immunol 1998; 114: 113-118.

187

Mouthon L. Treatment of ANCA-positive systemic Vasculitis with intravenous immunoglobulin. Rev Med Intern 1999; 20 (Suppl. 4): 431s-435s.

188

Muhle C., Reinhold-Keller E., Schmitt W.H. et al. MRI of nasal cavity, the paranasal sinuses and orbits in Wegener’s granulomatosis. Eur Radiol 1997; 7: 566-570.

189

Muller Kobold A.C., van Wijk R.T., Franssen C.F. et al. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener’s granulomatosis. Clin Exp Rheum 1999; 17: 433-440.

190

Naarendorp M., Kallemuchikkal U., Nuovo G.J. et al. Longterm efficacy of interferon alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28 (11): 2466-2473.

191

Nocente R., Gentiloni Silveri N., Bertazzoni G. et al. Delayed ANCA positivity in pulmonary-renal syndrome. Panminerva Med 2002; 44: 73-75.

192

Ohlsson S., Wieslander J., Segelmark M. Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin Exp Immunol 2003; 131: 528-535.

193

Olesinska M., Chwalinska H. Rheumatic syndromes during the course of HCV infection. Pol Merkuriusz 2002; 12 (68): 119-121.

194

Oplon P., Lunei F. Extrahepatic manifestations related to hepatitis C virus. Pathol Biol 1995; 43 (8): 709-715.

195

Pasqual M., Perrin I., Giostra E. et al. Hepatitis C virus in patients with cryoglobulinemia type II. Infect Dis 1990; 162: 569-570.

196

Pateron D., Fain O., Sehonnou J. et al. Severe necrotizing vasculitis in patients with hepatitis C virus infection treating by interferon. Clin Exp Rheumatol 1996; 14: 79-81.

197

PausJenssen E.S., Cocroft D.W. A case report of Wegener’s granulomatosis treated only with corticosteroids for 30 years. Amm Allergy Asthma Immunol 2003; 91 (1): 82-85.

198

Pawlotsky J.-M., Dhumeaux D., Bagot M. Hepatitis C virus in dermatology. Arch Dermatol 1955; 131: 1185-1193.

199

Pietrogrande M., Marelli F., Milani S. et al. Treatment of severe cryoglobulinemic syndrome with plasma exchange followed with high dose intravenous immunoglobulins: preliminary results. J Autoimmun 1999; Suppl.: S-95.

200

Pioltelli P., Maldifassi P., Vacca A. et al. GISC protocol experience in the treatment of essential mixed cryoglobulinemia. Clin Exp Rheum 1995; 13 (Suppl. 13): 187-190.

201

Plotnik S., Huppert A.S., Kantor G. Colchicine and leukocytoclastic vasculitis. Arthr Rheum 1989; 32: 1489-1490.

202

Pyrsopoulos N.T., Reddy K.R. Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep 2001; 3 (1): 71.

203

Rao J.K., Allen N.B., Pincus T. Limitations of the 1990 American College Rheumatology classification criteria in the diagnosis of vasculitis. Ann Int Med 1998; 129: 345-352.

204

Rasmussen N., Jayne D., Abramowicz D. et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101 (Suppl.): 29-34.

205

Reinhold-Keller E., De Groot K., Holl-Ulrich K. et al. Severe CNS manifestations as the clinical hallmark in generalized form Wegener’s granulomatosis consistently negative for antineutrophile cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheum 2001; 19 (5): 541-549.

206

Renaldini E., Spandiro S., Cerudelli B. et al. Cardiac involvement in Churg-Strauss syndrome: a follow-up of three cases. Evr Heart J 1993; 14: 1712.

207

Richter C., Schnabel A., Csernok E. et al. Treatment of antineutrophile cytoplasmic antibody (ANCA)-associated systemic vasculitis with high dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101: 2-7.

208

Rosenstok J.L., Stern L., Sherman W.H. et al. Fludarabine treatment of cryoglobulinemic glomerulonephritis. Am J kidney Dis 2002; 40 (3): 644-648.

209

Savage J., Winearls C.G., Evans D.J. et al. Microscopic poliarteriitis: presentation, pathology and prognosis. QJM 1985; 56: 467-483.

210

Schmitt W.H., Csernok E., Kobayashi S. et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arth Rheum 1998; 41: 445-452.

211

Schmitt W.H., van der Woude F.J. Clinical application of antineutrophil cytoplasmic antibody testing. Curr Opin Rheum 2004; 16 (1): 9-17.

212

Schnabel A., Holl-Ulllrich K., Dalhoff K. et al. Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Resp J 1997; 10: 2738-2743.

213

Schultz H., Heintz H., van Zandbergen G. et al. ANCA against the bacterial/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in Wegener’s granulomatosis patients. Clin Exp Rheum 2003; 21 (6): 763-766.

214

Schumaher H.R., Klippel J.H., Koopman W.J. Ed. Primer on the rheumatic disease. Atlanta: Arthritis Foundation 1993: 136-148.

215

Serra A., Cameron J., Turner D. et al. Vasculitis affecting kidney: presentation, histopathology and long-term outcome. QJM 1984; 53: 181-207.

216

Shafiei K., Luther E., Archie M. et al. Wegener’s Granulomatosis: Case Report and Brief Literary Review. JABFP 2003; 16 (6): 555-559.

217

Sharara A., Hunt C.M., Hamilton J.D. Hepatitis C. Ann Intern Med 1996; 125: 658-668.

218

Silvestri F., Pipan C., Barrillari G. et al. Prevalence of hepatitis C virus infection in patients with limphoprolipherative disorders. Blood 1996; 87: 4296-4301.

219

Slot M.C., Tervaert J.W., Boomsma M.M. et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine with relapse in proteinase 3-related vasculitis Arthr Rheum 2004; 51 (2): 269-273.

220

Slot M.C., Tervaert J.W., Franssen C.F. et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63 (2): 670-677.

221

Sneller M.C. Evaluation, treatment, and prophilaxis of infections complicating systemic vasculitis. Curr Opin Rheum 1998; 10: 38-44.

222

Sneller M., Hofmann G., Talar-Williams C. et al. An analysis of forty-two Wegener’s granulomatosis patients treated with methotrexate and prednisone. Arthr Rheum 1995; 38: 608-613.

223

Solans R., Bosch J.A., Perez-Bocanerga C. et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheum (Oxford) 2001; 40 (7): 763-771.

224

Stappaerts I., Bogers J., Ebo D. et al. c-ANCA positivity in a Belgian patient with pulmonary paracoccidiomycosis. Eur Respir J 1997; 10: 2419-2422.

225

Stegemann C.A., Cohen Tervaert J.W., Sluiter W.J. et al. Association of chronic nasal carriage of Staphilococcus aureus and higher relapse rates in Wegener’s granulomatosis. Ann Int Med 1994; 120: 12-17.

226

Stegemann C.A., Cohen Tervaert J.W., de Jong P.E. et al. Trimetoprim (Cotrimoxazole) for the prevention of relapses of Wegener’s granulomatosis. New Engl J Med 1996; 335: 16-20.

227

Straatsma B.R. Ocular manifestations of Wegener’s granulomatosis. Am J Med 1957; 63: 789-799.

228

Takeda Y., Aoki A., Tsuji T. et al. A case of non-specific interstitial pneumonia in patient with microscopic polyangiitis. Ryumachi 2003; 43 (4): 654-669.

229

Talar-Williams C., Hijazi Y.M., Walther M.M. et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener’s granulomatosis. Ann Int Med 1996; 124: 477-484.

230

Tarantino A., Campise M., Banfi G. et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-623.

231

Tatsis E., Schnabel A., Gross W.L. Interferon-á treatment of four patients with the Churg Strauss syndrome. Ann Int Med 1998; 129: 370-374.

232

Tavoni A., Mosca M., Ferri C. et al. Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheum 13 (Suppl. 13): S191-2195.

233

Tesar V., Rihova Z., Jancova E. et al. Current treatment strategies in ANCA-positive renal vasculitis from European randomized trials. Nephrol Dial Transpl 2003; 18 (Suppl. 5): v2-4.

234

Tomer Y., Lider O., Gilburd B. et al. Anti-neutrophil cytoplasmic antibody-enriched IgG induces adhesion of human T-lymphocytes to extracellular matrix proteins. Clin Immunol Immunopathol 1997; 83: 245-253.

235

Tonnel A.B., Gosset P.H., Molet S. et al. Interactions between endothelial cells and effector cells in allergic inflammation. Ann NY Acad Sci 1996; 796: 9-20.

236

Vacca A., Dammacco F. Deflazacort versus prednisone in treatment of EMC: a controlled clinical study. Int Arch Allerg Immunol 1992; 99: 306-313.

237

Valeriano-Marcet J., Spiera H. Treatment of Wegener’s granulomatosis with sulfamethoxazole-trimethoprim. Arch Int Med 1991; 151: 1649-1652.

238

Vizjak A., Rott T., Koselj-Kajtna M. et al. Histologic and immunologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis 2003; 41 (3): 539-549.

239

Wegener F. Uber generalizierte, septische Gefasserkrankungen. Verhandlungen der Deutschen Pathologischen Gesellschaft 1935; 29: 202-210.

240

Westman K.W., Bygren P.G., Olsson H. et al. Relapse rate, renal survival and cancer morbidity in patients with Wegener’s granulomatosis or microscopic poliangiitis with renal involvement. Am J Soc Nephrol 1998; 9: 842-852.

241

Westman K.W., Selga D., Isberg P.E. et al. High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by capture ensim-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Mephrol 2003; 14 (11): 2962-2933.

242

Wilson K.S., Alexander H.L. The relationship of periarteriitis nodosa to bronchial asthma and other forms of human hypersensitiveness. J Lab Clin Med 1945; 30: 195-203.

243

Wintrobe M.M., Bruel M.V. Hyperproteinemia associated with multiple myeloma: with report of a case in which an extraordinary hyperproteinemia was associated with trombosis of retinal veins and symptoms suggesting Raynaud’s disease. Bulletin of Jhons Hopkins Hospital 1933; 52: 156-172.

244

Wong V.S., Egner W., Elsey T. et al. Incidence, character and clinical relevance of mixed cryoglobulinemia in patients with chronic hepatitis C infection. Clin Exp Immunol 1996; 104: 25-31.

245

Xu X., Zhao M., Zhang Y. et al. Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens: a report 4 cases and literature review. Zhonghua Nei Ke Za Zhi 2002; 41 (6): 404-407.

The authors declare that there are no conflicts of interest present.